ADCC, CDC, and ADCP

Two important mechanisms by which antibody drugs kill targeted tumor cells are antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Creative Biolabs has the experience, expertise and capabilities to provide you with complete ADCC and CDC testing solutions. Based on state-of-the-art laboratories, we can ensure the efficacy and potency of your therapeutic antibodies by implementing strict QC standards.

ADCC & CDC Mechanism

Fig 1. Mechanism of Complement-dependent Cytotoxicity. (Boross, 2012)

Antibody-dependent cellular cytotoxicity (ADCC)

In antibody-dependent cellular cytotoxicity (ADCC), an Fcγ receptor (FcγR or FCGR) on the surface of an immune effector cell binds to the Fc region of an antibody, which specifically binds to a target cell. Cells that can mediate ADCC are non-specific cytotoxic cells such as natural killer cells, macrophages, monocytes, and eosinophils. When FCGR binds to the antibody, the FCGR ITAM is phosphorylated, which triggers the activation of effector cells and the secretion of various substances (lyase, perforin, granzyme, TNF) that mediate target cell destruction.

Complement-dependent cytotoxicity (CDC)

In complement-dependent cytotoxicity (CDC), C1q binds to antibodies, which triggers the complement cascade, resulting in the formation of a membrane attack complex (MAC) (C5b to C9) on the surface of target cells, and further resulting in a classical pathway of complement activation.

Antibody-dependent cellular phagocytosis (ADCP)

Antibody-dependent cellular phagocytosis (ADCP) is a key MOA for many antibody therapies. It is defined as a highly regulated process in which an antibody eliminates binding target and initiates phagocytosis by linking its Fc domain to a specific receptor on the phagocytic cell. Unlike ADCC, ADCP can mediate monocytes, macrophages, neutrophils and dendritic cells via FcγRIIa, FcγRI and FcγRIIIa, where FcγRIIa (CD32a) on macrophages represents the major pathway. To meet this need, Creative Biolabs has launched a primary cell-based ADCP assay service.

Moving Your Therapeutic Candidates Forward

  • ✔ Data readout driven by target cell lysis endpoint
  • ✔ High-throughput assay for large antibody screening
  • ✔ Extensive targeted tumor cell lines are used in ADCC assays to target cell surface antigens of interest to you
  • ✔ Automated, robust and highly repeatable high-throughput assay for large-scale screening
  • ✔ Flexible inspection design, easy to customize according to your project
  • ✔ Highly enriched natural killer cells from multiple donors
  • ✔ More than 10 years of combined screening experience

Creative Biolabs is willing to work with you to customize your own experimental plan, including target cell concentration, determination of the appropriate antibody/target ratio, and determination of sufficient antibody concentration range so as to produce a compelling dose-response curve. With the help of our unparalleled technology platform, Creative Biolabs delivers the most powerful and consistent results while maintaining the efficacy and potency of your antibody candidates.

Feel free to contact us for project quotations or more detailed information.

For lab research only, cannot be used for any clinical use.

Online Inquiry

Verification code
Click image to refresh the verification code.
Copyright © 2007 - 2021 Creative Biolabs. All Rights Reserved.